FDA Pushes to Classify 7-OH Sold in Vape Shops as Illicit Drug

Federal officials are taking aggressive steps to classify 7-hydroxymitragynine, or “7-OH,” as a Schedule I controlled substance, placing it in the same category as heroin and ecstasy. The substance, found in trace amounts in the leaves of the kratom plant, is being sold in highly concentrated forms in gas stations, convenience stores, and vape shops across the country, often marketed as a way to relax, focus, or reduce pain.

The U.S. Food and Drug Administration (FDA) warns that these products are pushing Americans towards a new opioid crisis. “Scientifically, by definition, it is an opioid,” stated FDA Commissioner Dr. Marty Makary at a press conference. He explained that while 7-OH is found in kratom, the products being sold are a “concentrated synthetic potent form,” often misleadingly marketed as “kratom extracts” or “enhanced kratom.” The FDA notes its chemical makeup is similar to other serious drugs and can be more potent than morphine.

Concerns are growing over its potential for abuse, particularly among young adults. One vape shop employee noted that people aged 22-23 were frequently purchasing the product, sometimes returning just hours later for more. The products are readily available in liquid and tablet forms, typically costing between $25-$30.

“When there’s availability, that can become a crisis,” stated HHS Secretary Robert F. Kennedy Jr. The push to make 7-OH a Schedule I substance would mark it as having the highest potential for abuse with no accepted medical use. The Drug Enforcement Administration (DEA) is currently reviewing the FDA’s recommendation, a process that will include a period for public comment before a final decision is made.

News source: FDA pushing to classify products sold at gas stations, vape shops as illicit drug

Author
Recent Posts

Sophia Bennett

Author at Ecigator

Sophia Bennett has dedicated her career to monitoring and analyzing the regulatory landscape and news within the vape industry. With a keen eye for the evolving policies that shape this dynamic market, Sophia brings a critical perspective to her commentary and reports.

Latest posts by Sophia Bennett (see all)